A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2019-06-14

Summary

This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382

• Phase: Phase 2

Details

• Lead Sponsor: AstraZeneca
• Collaborator: MedImmune LLC
• Treatments: Liraglutide; Metformin